bluuebunny/crossref_metadata_2025_split huggingface dataset:
Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
Authors: Cosgrove David P. , Reese Emily S. , Fulcher Nicole M. , Bobiak Sarah S. , Lamy Francois‐Xavier , Allignol Arthur , Boyd Marley , Mahmoudpour Seyed H. 
Published: October 2022

AbstractBackgroundLimited data are available regarding second‐line (2 L) treatment for advanced or metastatic biliary tract cancers (BTC) in the US real‐world setting. This study explores the rapidly evolving and growing treatment landscape in the 2 L setting for advanced or metastatic BTC with a large cohort of patients treated in a community oncology setting.MethodsAdult patients with BTC initiating 2 L treatment after a platinum‐containing first‐line between 1/1/10‐ and 6/30/19 were identified from the US Oncology Network electronic healthcare record database and followed through 12/31/19. Baseline patient and treatment characteristics were analyzed descriptively, including overall response rate (ORR) in the real‐world clinical setting. Kaplan–Meier methods were used to measure duration of response, progression‐free survival (PFS), and overall survival (OS).ResultsThe overall population (N = 160) included 74 patients (46.3%) with intrahepatic cholangiocarcinoma, 41 (25.6%) with extrahepatic cholangiocarcinoma, and 45 (28.1%) with gallbladder cancer. Thirty unique 2 L regimens were recorded for the study population, with folinic acid, fluorouracil and oxaliplatin (FOLFOX, 34.4%) and capecitabine monotherapy (20.0%) being the most common. ORR was 7.5% (95% CI, 3.9%–12.7%). From 2 L initiation, median PFS was 2.8 months (95% CI, 2.4–3.3 months), and median OS was 5.2 months (95% CI, 4.2–6.7 months).ConclusionResults from this study provide real‐world evidence that although patients treated in the community oncology setting receive a wide variety of 2 L treatments, the regimens are consistent with those recommended by guidelines. Although responses are observed with 2 L treatment, duration is brief and associated with poor OS in patients with advanced or metastatic disease.
Perceived deception and online repurchase intention: The moderating effect of product type and consumer regulatory orientation
Authors: Wang Xinyue , Ashraf Abdul R. , Thongpapanl Narongsak , Wang Kai‐Yu 
Published: October 2022

AbstractLimited by e‐tailers' ability to present accurate information about their products, consumers often misunderstand and misinterpret product messaging, which can heighten their perception of deception among e‐tailers and result in unfavorable consumer behaviors and actions. Integrating perceived deception and existing consumer behavior theories, this research examines the intricate relationships between product type (hedonic vs. utilitarian), consumer regulatory orientation (promotion vs. prevention), and their interactive effect on the relationship between perceived deception and consumer repurchase intention in online settings. Across three studies, we identified a less negative impact due to perceived deception for online repurchase intention of hedonic products than for utilitarian products. After perceived deception occurs, promotion‐oriented individuals show a higher online repurchase intention compared to prevention‐oriented individuals. Furthermore, the fit between promotion orientation and hedonic products works best to attenuate perceived deception's unfavorable impact on online repurchase intention. In contrast, the fit between prevention orientation and utilitarian products leads to the lowest online repurchase intentions. Also, e‐tailers can increase repurchase intentions by emphasizing the hedonic attribute, and instigating promotion intention would help mitigate the negative effects of perceived deception.
A case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic disorders
Authors: Wei Lijian , Tang Yuting , Wu Zhuohua , Xu Pingyi , Mo Mingshu 
Published: October 2022

AbstractThis is a case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic events. His fibrinogen concentration was negatively correlated with thrombin time and prothrombin time and abnormally negatively correlated with plasma D‐dimer levels. The individualized standard for fibrinogen concentration may help to balance thrombotic and hemorrhagic events for this disease.
Put the Blue Genes on
Authors: Hübner Karl 
Published: October 2022

ZusammenfassungWie steht es eigentlich um die „blaue Rose“, die es in der Natur nicht gibt und die sicher so etwas wie die Königin der blauen Blumen wäre? Seit Jahrzehnten wird daran geforscht, doch bislang ohne durchschlagenden Erfolg – Spurensuche und Überblick.
Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant
Authors: Tyler Timothy , Schultz Armin , Venturini Alessio , Giuliano Claudio , Bernareggi Alberto , Spezia Riccardo , Voisin Daniel , Stella Valentino 
Published: October 2022

AbstractOral NEPA is the fixed‐combination antiemetic comprising netupitant (neurokinin‐1 receptor antagonist [NK1RA]) and palonosetron (5‐hydroxytryptamine‐3 receptor antagonist [5‐HT3 RA]). Intravenous (IV) NEPA, containing fosnetupitant, a water‐soluble N‐phosphoryloxymethyl prodrug of netupitant, has been developed. Fosnetupitant does not require excipients or solubility enhancers often used to increase IV NK1RA water solubility, preventing the occurrence of hypersensitivity and infusion‐site reactions associated with these products. In this phase 1 study, subjects received a 30‐minute placebo or fosnetupitant (17.6–353 mg) infusion and an oral NEPA or placebo capsule, with 2‐sequence crossover treatment for fosnetupitant 118‐ to 353‐mg dose cohorts. IV fosnetupitant safety and pharmacokinetics were evaluated, and its equivalence to an oral netupitant 300‐mg dose was defined. Overall, 158 healthy volunteers were enrolled. All adverse events (AEs) were mild or moderate in intensity. Doppler‐identified infusion‐site asymptomatic thrombosis occurred in 5.4% (fosnetupitant) and 1.2% (oral NEPA) of subjects. The frequency or number of treatment‐related AEs did not increase with ascending fosnetupitant doses. The most common treatment‐related AEs were headache (fosnetupitant, 8.1%; oral NEPA, 12.7%) and constipation (fosnetupitant, 1.4%; oral NEPA, 7.5%). A fosnetupitant 235‐mg dose was equivalent, in terms of netupitant exposure, to 300‐mg oral netupitant. The safety profile of a single fosnetupitant 235‐mg infusion was similar to that of single‐dose oral NEPA.
Lactobacillus paracaseiN1115 attenuates obesity in high‐fat diet‐induced obese mice
Authors: Sun Yanan , Chen Shanbin , Ren Fazheng , Li Yixuan 
Published: October 2022

AbstractDisruption of the microbial structure of intestinal bacteria due to a high‐fat diet (HFD) is closely associated with metabolic disorders, such as obesity and type 2 diabetes. Probiotics are known to modulate the gut microbiota; therefore, we demonstrated the capability of Lactobacillus paracasei N1115 (LC‐N1115) to attenuate obesity. Four‐week‐old male C57BL/6J mice were fed a HFD for 12 weeks to induce obesity and were then randomized to supplemented placebo or LC‐N1115 treatment group for another 12 weeks. LC‐N1115 treatment reduced weight gain and liver fat accumulation as well as triglyceride, total cholesterol, and low‐density lipoprotein cholesterol levels. The administration of LC‐N1115 suppressed the expression of fatty acid synthase, interleukin‐1 β, and toll‐like receptor 4. Notably, the operational taxonomic units that negatively and positively correlated with the obesity phenotypes were enriched and reduced, respectively, in the LC‐N1115 treatment group. These results indicate that LC‐N1115 attenuates obesity by modulating the gut microbiota and the expression of lipid synthesis and proinflammatory cytokine genes.
Hydraulic fracture to enhance coalbed methane recovery by using coated ceramsite
Authors: Zou Mingjun , Yao Linlin , Zhang Miao , Huang Zhiquan , Xu Rongchao , Ding Zibin , Zhang Xingsheng 
Published: October 2022

AbstractIn recent decades, coated ceramsite has become popular due to its low density, high compressive strength, and high flow conductivity, and it has been applied in many areas in construction field and chemical industry. In the area of hydraulic fracture, limited relevant literature can be found, especially on unconventional reservoirs with soft coals. In this paper, numerical simulation is performed to obtain migration regularity and granularity proportion using coated ceramsite, and it indicates that the biggest proppant concentration and strongest flow conductivity can be achieved under the granularity proportion of 1:6:2 with respective coated ceramsites of 40/60, 16/40, and 12/20 mesh. Then, a series of construction parameters are calculated and optimized to receive a best fracture performance by using mathematical methods, including total proppant volume, each proppant volume, fluid injection rate, fluid injection volume, and proppant concentration, etc. Results from micro seismic monitoring indicate that the actual fracture performance matches well with the simulated performance by using coated ceramsite and has an obviously longer fracture length and a bigger proppant concentration compared with performances by using quartz sand. Meanwhile, comparisons for gas productions fractured by coated ceramsite and quartz sand reveal that coated ceramsite can achieve a better drainage performance. All of the above can be a guide for hydraulic fracture and useful for enhancing coalbed methane recovery. © 2022 Society of Chemical Industry and John Wiley & Sons, Ltd.
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
Authors: Merli Michele , Ferrarini Isacco , Merli Francesco , Busca Alessandro , Mina Roberto , Falini Brunangelo , Bruna Riccardo , Cairoli Roberto , Marchetti Monia , Romano Alessandra , Cavo Michele , Arcaini Luca , Trentin Livio , Cattaneo Chiara , Derenzini Enrico , Fracchiolla Nicola Stefano , Marchesi Francesco , Scattolin Annamaria , Billio Atto , Bocchia Monica , Massaia Massimo , Gambacorti‐Passerini Carlo , Mauro Francesca Romana , Gentile Massimo , Mohamed Sara , Della Porta Matteo Giovanni , Coviello Elisa , Cilloni Daniela , Visani Giuseppe , Federici Augusto Bramante , Tisi Maria Chiara , Cudillo Laura , Galimberti Sara , Gherlinzoni Filippo , Pagano Livio , Guidetti Anna , Bertù Lorenza , Corradini Paolo , Passamonti Francesco , Visco Carlo 
Published: October 2022

AbstractCOVID‐19, the disease caused by SARS‐CoV‐2, is still afflicting thousands of people across the globe. Few studies on COVID‐19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID‐19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID‐19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID‐19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow‐up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID‐19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID‐related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.
Should attention be paid to the cone depth in the fully visible transformation zone? Retrospective analysis of 517 patients with cervical intraepithelial neoplasia grade 3
Authors: Giannella Luca , Delli Carpini Giovanni , Di Giuseppe Jacopo , Gardella Barbara , Bogani Giorgio , Monti Ermelinda , Liverani Carlo Antonio , Roncella Elena , Raspagliesi Francesco , Spinillo Arsenio , Vercellini Paolo , Ciavattini Andrea 
Published: October 2022

AbstractObjectiveThe predictors of positive endocervical margin (EM) and a cone‐depth cutoff value are not established in the fully visible transformation zone (TZ). The present study aimed to assess the independent variables associated with positive EM in women with high‐grade cervical intraepithelial neoplasia (CIN) and fully visible TZ.MethodsThe current investigation was a retrospective study including women with fully visible TZ and CIN 3 cone histology between 2014 and 2019. The sample was divided into women with positive versus those with negative EM. Univariate and multivariate analyses were performed. Finally, receiver operating characteristic curve analysis was also used.ResultsA total of 123 of 517 women (23.8%) showed positive EM at conization. Multivariate analysis found a positive association with type 2 TZ (odds ratio [OR], 2.17 [95% confidence interval (CI), 1.19–3.94]) and lesion extension ≥2 cervical quadrants (OR, 35.57 [95% CI, 17.96–70.45]). Cone depth was inversely related to positive EM (OR, 0.71 [95% CI, 0.63–0.80]). In women with type 2 TZ and lesion extension ≥2 cervical quadrants, the cutoff value was achieved at 8‐mm cone depth (area under the curve, 0.79 [95% CI, 0.67–0.90]).ConclusionIn women with high‐grade CIN and fully visible TZ undergoing conization, the lesion extension and the TZ subtype (1 or 2) should be considered. A no less than 9‐mm cone depth provided a fair predictive value in achieving free EM.
Impact of pharmacist‐led chronic disease management in a Federally Qualified Health Center
Authors: McCarthy Caitlin , Thomas Bateman M. 
Published: October 2022

AbstractIntroductionThere is growing interest in pharmacist‐led chronic disease management (CDM) for underserved populations such as those treated within Federally Qualified Health Centers (FQHCs).ObjectivesTo assess the impact of adding a pharmacist to the healthcare team within an FQHC for CDM.MethodsThis is a non‐randomized, 6‐month prospective pilot study whereby any member of the healthcare team could refer a patient to receive CDM from a pharmacist. The primary outcome is change in disease control as measured by primary clinical endpoint. Primary clinical endpoints for the most common disease states include glycated hemoglobin (A1C) for type 2 diabetes mellitus (T2DM), systolic blood pressure (SBP) for hypertension, Generalized Anxiety Disorder‐7 (GAD‐7) score for anxiety, and Patient Health Questionnaire‐9 (PHQ‐9) score for depression. Primary clinical endpoints are compared using a paired t test for the modified intention‐to‐treat population. Secondary outcomes include change in self‐reported health and healthcare utilization and difference in satisfaction with care between the primary care provider (PCP) and pharmacist.ResultsThree hundred patients were enrolled of whom 199 were included. Most patients were referred by their PCP. Statistically significant differences in the mean primary endpoint were observed for all disease states with at least 20 participants, including T2DM (n = 96, change in A1C ‐2.1%, P < 0.001), hypertension (n = 32, change in SBP ‐29.7 mmHg, P < 0.001), anxiety (n = 25, change in GAD‐7 score − 7, P < 0.001), and depression (n = 22, change in PHQ‐9 score −11.1, P < 0.0001). While statistically significant changes in self‐reported healthcare and healthcare utilization were not observed, patients were more satisfied with care.ConclusionWhen provided with prescriptive authority and working within an interdisciplinary primary care team, pharmacists were able to impact clinical and humanistic outcomes in the FQHC, leading to improved CDM for a variety of illnesses. More studies should be conducted to validate these results in other settings.
Neurological symptoms and neuronal damage markers in acute COVID‐19: Is there a correlation? A pilot study
Authors: Sahin Burc E. , Celikbilek Asuman , Kocak Yusuf , Ilanbey Bilal , Saltoglu Gamze T. , Konar Naime M. , Hizmali Lokman 
Published: October 2022

AbstractA wide spectrum of neurological symptoms (NS) has been described in patients with COVID‐19. We examined the plasma levels of neuron‐specific enolase (NSE) and neurofilament light chain (NFL) together, as neuronal damage markers, and their relationships with clinical severity in patients with NS at acute COVID‐19. A total of 20 healthy controls and 59 patients with confirmed COVID‐19 were enrolled in this pilot prospective study. Serum NSE and NFL levels were measured by using the enzyme‐linked immunoassay method from serum samples. Serum NSE levels were found to be significantly higher in the severe group than in the nonsevere group (p = 0.034). However, serum NFL levels were similar between the control and disease groups (p > 0.05). For the mild group, serum NFL levels were significantly higher in patients with the sampling time ≥5 days than in those with the sampling time <5 days (p = 0.019). However, no significant results for NSE and NFL were obtained in patients with either single or multiple NS across the groups (p > 0.05). Increased serum NSE levels were associated with disease severity regardless of accompanied NS in patients with acute COVID‐19 infection. However, serum NFL levels may have a role at the subacute phase of COVID‐19.
Learning deep representations of enzyme thermal adaptation
Authors: Li Gang , Buric Filip , Zrimec Jan , Viknander Sandra , Nielsen Jens , Zelezniak Aleksej , Engqvist Martin K. M. 
Published: October 2022

AbstractTemperature is a fundamental environmental factor that shapes the evolution of organisms. Learning thermal determinants of protein sequences in evolution thus has profound significance for basic biology, drug discovery, and protein engineering. Here, we use a data set of over 3 million BRENDA enzymes labeled with optimal growth temperatures (OGTs) of their source organisms to train a deep neural network model (DeepET). The protein‐temperature representations learned by DeepET provide a temperature‐related statistical summary of protein sequences and capture structural properties that affect thermal stability. For prediction of enzyme optimal catalytic temperatures and protein melting temperatures via a transfer learning approach, our DeepET model outperforms classical regression models trained on rationally designed features and other deep‐learning‐based representations. DeepET thus holds promise for understanding enzyme thermal adaptation and guiding the engineering of thermostable enzymes.
Efficient excited‐state intramolecular proton transfer in acridone derivatives—A case study of Paratrimerin C
Authors: Nguyen Thi Le Anh , Truong Dinh Hieu , Ngo Thi Chinh , Dao Duy Quang 
Published: October 2022

AbstractParatrimerin C is a natural acridone antioxidant that is also potent as an anti‐UV agent. The photophysical process of Paratrimerin C, including the absorption and emission and the excited state intramolecular proton transfer (ESIPT) mechanism, is studied herein with time‐dependent density functional theory. The solvent effect on ESIPT is studied for polar (water) and non‐polar (benzene) solvents employing the Integral Equation Formalism Polarization Continuum Model and adding up to three explicit molecules of solvent. The normal and tautomer forms of the Paratrimerin C at the ground‐ and excited‐state structures are studied at the M06‐2X/6‐311++G(d,p) level of theory. The potential energy curves along the reaction coordinates indicate that the ESIPT is a barrier‐less reaction, and the variation of OdOa distance in the excited state shows significant molecular structure deformation along the proton transfer process following the normal‐to‐tautomerism pathway. The obtained results suggest using of acridone derivatives as efficient and tunable fluorescence molecules besides their biological activities.
Do trait‐level emotion regulation strategies moderate associations between retrospective reports of childhood trauma and prospective changes in systemic inflammation?
Authors: Jones Emily J. , Marsland Anna L. , Gianaros Peter J. 
Published: October 2022

AbstractChildhood trauma may confer risk for poorer adult health through changes in systemic inflammation. Emotion regulation may plausibly moderate associations between childhood trauma and adult psychological well‐being, but it remains unclear whether moderation effects extend to differences in systemic inflammation. To examine whether childhood trauma and emotion regulation separately and interactively predict prospective changes in C‐reactive protein (CRP) and interleukin‐6 (IL‐6) and whether biopsychosocial factors account for observed associations. Healthy midlife adults (N = 331) retrospectively reported on childhood trauma, current trait‐level cognitive reappraisal and expressive suppression, and had their blood drawn. At baseline and then a median of 2.85 years later, 279 of the 331 participants had their blood drawn, body mass index calculated, and reported on health behaviours (smoking, sleep), psychological distress (perceived stress, depressive symptoms), and years of education. Childhood trauma predicted prospective increases in CRP (B = 0.004, p = 0.049), which were partially accounted for by differences in adiposity, psychological distress, and health behaviours. In contrast, cognitive reappraisal predicted prospective decreases in IL‐6 (B = −0.007, p = 0.006), which were independent of biopsychosocial influences. Cognitive reappraisal further moderated the association between childhood trauma and prospective changes in IL‐6 (B = −0.001, p = 0.012) such that childhood trauma predicted greater IL‐6 increases but only among adults lower in cognitive reappraisal (B = 0.006, p = 0.007). There were no main or moderation effects of expressive suppression (ps > 0.05). Cognitive reappraisal may attenuate IL‐6 changes over time and may moderate the prospective association between childhood trauma and systemic inflammation in midlife.
V‐model with fuzzy quality function deployments for mobile application development
Authors: Lim Chong Hon , Chin Jeng Feng 
Published: October 2022

AbstractMobile application (app) development is a subset of software development distinguished by a short development life cycle, rapidly changing business requirements, mobile device technical specifications, and operating system compatibility. The study presents a V‐model mobile app development technique that combines two fuzzy quality function deployment (FQFD) phases. In mobile app development, user requirements are often misunderstood, resulting in poor mobile app design. The research motivation for employing FQFD is to obtain more accurate deductions of human (user or design team) inputs affected by intrinsic vagueness and ambiguity in linguistics. The combination hence delivers synergistic benefits, where FQFDs more effectively solicits and breaks down the voice of the customer (VOC) and system requirements, and the V‐model aligns the development to the broken‐down requirements. The development of an online statistical process control app was demonstrated. FQFD structurally related user requirements, system requirements, and design strategies in the V‐model's verification phases. The validation phases used test plans created during the verification phases to detect and correct programming errors. In the final validation stage, the focus group agreed that the mobile app met all of the user requirements. This study adds to the methodology's novelty by proposing and demonstrating the integration of the FQFD and V‐model into the development of mobile apps. As a result of the limitation, other areas of software engineering, such as time and resource coordination and release management, are not considered.